NO20084819L - Substituerte pyrazinonderivater for anvendelse som en medisin - Google Patents
Substituerte pyrazinonderivater for anvendelse som en medisinInfo
- Publication number
- NO20084819L NO20084819L NO20084819A NO20084819A NO20084819L NO 20084819 L NO20084819 L NO 20084819L NO 20084819 A NO20084819 A NO 20084819A NO 20084819 A NO20084819 A NO 20084819A NO 20084819 L NO20084819 L NO 20084819L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- medicine
- anxiety
- mood
- pyrazinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Den foreliggende oppfinnelsen omhandler substituert pyriazinonderivater ifølge den generelle formelen (I) (I) et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav, en stereokjemisk isomerisk form derav, en N-oksid derav eller et kvaternært ammoniumsalt derav, hvori variablene er definert i krav 1, som har selektiv a2C-adrenoseptorantagonistaktivitet. Den relaterer seg også videre til deres fremstilling, sammensetninger omfattende dem og deres anvendelse som en medisin. Forbindelsene ifølge oppfinnelsen er nyttige for forebyggingen og/eller behandlingen av sentralnervesystemforstyrrelser, humørforstyrrelser, angstlidelser, stressrelaterte lidelser assosiert med depresjon og/eller angst, kognitive forstyrrelser, personlighetsforstyrrelser, schizoaffektive lidelser, Parkinson's sykdom, demens av Alzheimers typen, kroniske smertetilstander, nevrodegenerative lidelser, avhengighetslidelser, humørforstyrrelser og seksuell dysfunksjon. 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06112814 | 2006-04-20 | ||
PCT/EP2007/053821 WO2007122173A1 (en) | 2006-04-20 | 2007-04-19 | Substituted pyrazinone derivatives for use as a medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084819L true NO20084819L (no) | 2008-11-17 |
Family
ID=37005820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084819A NO20084819L (no) | 2006-04-20 | 2008-11-17 | Substituerte pyrazinonderivater for anvendelse som en medisin |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090111801A1 (no) |
EP (1) | EP2013202B1 (no) |
JP (1) | JP2009534356A (no) |
KR (1) | KR20080109789A (no) |
CN (1) | CN101426788A (no) |
AT (1) | ATE471322T1 (no) |
AU (1) | AU2007242859A1 (no) |
BR (1) | BRPI0711574A2 (no) |
CA (1) | CA2646652A1 (no) |
DE (1) | DE602007007206D1 (no) |
EA (1) | EA200870452A1 (no) |
IL (1) | IL194740A0 (no) |
MX (1) | MX2008013458A (no) |
NO (1) | NO20084819L (no) |
WO (1) | WO2007122173A1 (no) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101152659B1 (ko) | 2009-10-09 | 2012-06-15 | 한국과학기술연구원 | 세로토닌 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 동시에 가지는 설폰아마이드 화합물 |
EP3464272B1 (en) | 2016-06-07 | 2021-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1036065T3 (da) * | 1997-12-04 | 2004-08-30 | Allergan Inc | Substituerede imidazolderivater med agonistlignende aktivitet ved alfa-2B- eller 2B/2C-adrenerge receptorer |
EP1322628A2 (en) * | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
-
2007
- 2007-04-19 BR BRPI0711574-1A patent/BRPI0711574A2/pt not_active IP Right Cessation
- 2007-04-19 DE DE602007007206T patent/DE602007007206D1/de active Active
- 2007-04-19 EP EP07728283A patent/EP2013202B1/en active Active
- 2007-04-19 AU AU2007242859A patent/AU2007242859A1/en not_active Abandoned
- 2007-04-19 KR KR1020087023909A patent/KR20080109789A/ko not_active Application Discontinuation
- 2007-04-19 CN CNA2007800139794A patent/CN101426788A/zh active Pending
- 2007-04-19 EA EA200870452A patent/EA200870452A1/ru unknown
- 2007-04-19 JP JP2009505891A patent/JP2009534356A/ja active Pending
- 2007-04-19 AT AT07728283T patent/ATE471322T1/de not_active IP Right Cessation
- 2007-04-19 CA CA002646652A patent/CA2646652A1/en not_active Abandoned
- 2007-04-19 WO PCT/EP2007/053821 patent/WO2007122173A1/en active Application Filing
- 2007-04-19 US US12/297,670 patent/US20090111801A1/en not_active Abandoned
- 2007-04-19 MX MX2008013458A patent/MX2008013458A/es not_active Application Discontinuation
-
2008
- 2008-10-22 IL IL194740A patent/IL194740A0/en unknown
- 2008-11-17 NO NO20084819A patent/NO20084819L/no unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009534356A (ja) | 2009-09-24 |
IL194740A0 (en) | 2009-08-03 |
AU2007242859A1 (en) | 2007-11-01 |
BRPI0711574A2 (pt) | 2011-11-16 |
DE602007007206D1 (de) | 2010-07-29 |
CN101426788A (zh) | 2009-05-06 |
US20090111801A1 (en) | 2009-04-30 |
CA2646652A1 (en) | 2007-11-01 |
KR20080109789A (ko) | 2008-12-17 |
EA200870452A1 (ru) | 2009-04-28 |
MX2008013458A (es) | 2008-10-30 |
WO2007122173A1 (en) | 2007-11-01 |
ATE471322T1 (de) | 2010-07-15 |
EP2013202A1 (en) | 2009-01-14 |
EP2013202B1 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200635906A (en) | Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine | |
IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
WO2007141200A8 (en) | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
CY1112601T1 (el) | Υποκατεστημενα παραγωγα 1-πιπεριδιν-4-υλ-4-πυρρολιδιν-3-υλ-πιπεραζινης και χρηση αυτων ως ανταγωνιστων νευροκινινης | |
MX2011011489A (es) | Derivados de isoxazol-piridina. | |
HRP20041179B1 (hr) | Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti | |
PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
WO2010039186A3 (en) | Benzoxazoles useful as faah modulators and uses thereof | |
TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
PL1853232T3 (pl) | Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania | |
DE602005016836D1 (de) | Chotischer und anxiolytischer aktivität | |
NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
ATE440826T1 (de) | Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen | |
WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
TH80312B (th) | อนุพันธ์ซับสทิทิวเทดไทรแอโซโลน, เททราโซโลน และอิมิแดโซโลน สำหรับใช้เป็นยา | |
EA201990188A1 (ru) | Производные 5,7-дигидропирролопиридина |